Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Diamondback Energy Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Diamondback Energy Inc trades at $198 (market cap $55.49B). The key difference: Diamondback Energy Inc is far larger — about 19.4× Dyne Therapeutics Inc. Common Stock's market cap, and Diamondback Energy Inc pays a 2.22% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Diamondback Energy Inc for 70 Days on average.
| DYN | FANG | |
|---|---|---|
Market Cap | $2.86B | $55.49B |
Volume | 3,341,579 | 2,752,760 |
Sector | Health | Energy |
52-Week High | $26.78 | $213.69 |
52-Week Low | $14.60 | $137.29 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $2.18B | $67.65B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Diamondback Energy (FANG) trades at $197.51, up 1.23% with strong analyst support (90.57% buy rating) and a $232.54 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, while cash flow from operations improved to $8.76B in 2025. The stock shows bullish technical signals with support at $194 and resistance at $200, though RSI levels indicate potential overbought conditions.
FANG offers growth potential with rising revenue and operational efficiency, but faces risks from oil price volatility and declining profit margins. Institutional buying and positive Permian Basin developments support upside, while insider selling and competitive pressures warrant caution for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
